Objective: We aimed to investigate cardiovascular disease (CVD) risk and risk factors and evaluate the relationship among disease activity, inflammation markers, and uric acid levels in patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA). Materials and Methods: In this study, 98 patients with RA, 41 patients with SpA, and 95 controls were included. Participants’ demographic features, levels of body mass index (BMI), blood pressure (BP), waist circumference, glucose, cholesterol, uric acid, disease activity, and metabolic syndrome (MetS) prevalence were recorded. The 10-year CVD risk and heart age were calculated by using the Framingham risk score. Results: The mean BMI, systolic BP, diastolic BP, and waist circumference were higher in RA patients. There was no difference among patients with RA, those with SpA, and controls in terms of MetS prevalence (43.9%, 41.5%, and 35.8%, respectively, p=0.510) and 10-year CVD risk (12.7±10.2, 9.2±8.7, and 11.4±10.8, respectively, p=0.174). Higher uric acid levels were indicated in patients with MetS in both RA and SpA groups. Uric acid levels were associated with the Framingham score in RA patients. Conclusion: In patients with RA and SpA, CVD risk was determined to be similar to that of the general population. On the other hand, the uric acid level was found to be correlated with the risk of MetS, and uric acid is associated with CVD risk, especially in patients with RA.
Malesci D, Niglio A, Mennillo GA, Buono R, Valentini G, La Montagna G. High prevalence of metabolic syndrome in patients with ankylosing spondylitis. Clin Rheumatol 2007; 26(5): 710–4. [CrossRef]
Papadakis JA, Sidiropoulos PI, Karvounaris SA, Vrentzos GE, Spanakis EK, Ganotakis ES, et al. High prevalence of metabolic syndrome and cardiovascular risk factors in men with ankylosing spondylitis on anti-TNFalpha treatment: correlation with disease activity. Clin Exp Rheumatol 2009; 27(2): 292–8.
Ferraz-Amaro I, González-Juanatey C, López-Mejias R, RianchoZarrabeitia L, González-Gay MA. Metabolic syndrome in rheumatoid arthritis. Mediators Inflamm 2013; 2013: 710928. [CrossRef]
da Cunha VR, Brenol CV, Brenol JC, Fuchs SC, Arlindo EM, Melo IM, et al. Metabolic syndrome prevalence is increased in rheumatoid arthritis patients and is associated with disease activity. Scand J Rheumatol 2012; 41(3): 186–91. [CrossRef]
Mok CC, Ko GT, Ho LY, Yu KL, Chan PT, To CH. Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. Arthritis Care Res (Hoboken) 2011; 63(2): 195–202. [CrossRef]
Ciarla S, Struglia M, Giorgini P, Striuli R, Necozione S, Properzi G, et al. Serum uric acid levels and metabolic syndrome. Arch Physiol Biochem 2014; 120(3): 119–22. [CrossRef]
de Miranda JA, Almeida GG, Martins RI, Cunha MB, Belo VA, dos Santos JE, et al. [Article in Portuguese] [The role of uric acid in the insulin resistance in children and adolescents with obesity]. Rev Paul Pediatr 2015; 33(4): 431–6. [CrossRef]
Kuo D, Crowson CS, Gabriel SE, Matteson EL. Hyperuricemia and incident cardiovascular disease and noncardiac vascular events in patients with rheumatoid arthritis. Int J Rheumatol 2014; 2014: 523897.
Chavan VU, Ramavataram D, Patel PA, Rupani MP. Evaluation of serum magnesium, lipid profile and various biochemical parameters as risk factors of cardiovascular diseases in patients with rheumatoid arthritis. J Clin Diagn Res 2015; 9(4): BC01–5. [CrossRef]
Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21(12): 2286–91.
Lukas C, Landewé R, Sieper J, Dougados M, Davis J, Braun J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009; 68(1): 18–24. [CrossRef]
Prevoo ML, van ‘t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38(1): 44–8. [CrossRef]
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106(25): 3143–421. [CrossRef]
Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97(18): 1837–47. [CrossRef]
Agarwal D, Malaviya AN. A study of conventional cardiovascular disease (CVD) risk factors in rheumatoid arthritis (RA) Indians. Indian Journal of Rheumatology 2013; 8(3): 19–23. [CrossRef]
Wibetoe G, Ikdahl E, Rollefstad S, Olsen IC, Bergsmark K, Kvien TK, et al. Cardiovascular disease risk profiles in inflammatory joint disease entities. Arthritis Res Ther 2017; 19(1): 153. [CrossRef]
Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJ, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis 2017; 76(1): 17–28. [CrossRef]
Corrales A, Dessein PH, Tsang L, Pina T, Blanco R, Gonzalez-Juanatey C, et al. Carotid artery plaque in women with rheumatoid arthritis and low estimated cardiovascular disease risk: a cross-sectional study. Arthritis Res Ther 2015; 17(1): 55. [CrossRef]
Corrales A, González-Juanatey C, Peiró ME, Blanco R, Llorca J, González-Gay MA. Carotid ultrasound is useful for the cardiovascular risk stratification of patients with rheumatoid arthritis: results of a population-based study. Ann Rheum Dis 2014; 73(4): 722–7. [CrossRef]
Rueda-Gotor J, Llorca J, Corrales A, Blanco R, Fuentevilla P, Portilla V, et al. Carotid ultrasound in the cardiovascular risk stratification of patients with ankylosing spondylitis: results of a population-based study. Clin Exp Rheumatol 2016; 34(5): 885–92. [CrossRef]
Genre F, López-Mejías R, Miranda-Filloy JA, Ubilla B, Carnero-López B, Blanco R, et al. Adipokines, biomarkers of endothelial activation, and metabolic syndrome in patients with ankylosing spondylitis. Biomed Res Int 2014; 2014: 860651. [CrossRef]
Akbal A, Selçuk B, Gürcan A, Kurtaran A, Ersöz M, Akyüz M. Romatoid Artritli Hastalarda Metabolik Sendrom. Arch Rheumatol 2009; 24(4): 202–5.
Bilecik NA, Tuna S, Samancı N, Balcı N, Akbaş H. Prevalence of metabolic syndrome in women with rheumatoid arthritis and effective factors. Int J Clin Exp Med 2014; 7(8): 2258–65.
Karimi M, Mazloomzadeh S, Kafan S, Amirmoghadami H. The frequency of metabolic syndrome in women with rheumatoid arthritis and in controls. Int J Rheum Dis 2011; 14(3): 248–54. [CrossRef]
Karvounaris SA, Sidiropoulos PI, Papadakis JA, Spanakis EK, Bertsias GK, et al. Metabolic syndrome is common among middle-to-older aged Mediterranean patients with rheumatoid arthritis and correlates with disease activity: a retrospective, cross-sectional, controlled, study. Ann Rheum Dis 2007; 66(1): 28–33. [CrossRef]
Sahebari M, Goshayeshi L, Mirfeizi Z, Rezaieyazdi Z, Hatef MR, Ghayour-Mobarhan M, et al. Investigation of the association between metabolic syndrome and disease activity in rheumatoid arthritis. ScientificWorldJournal 2011; 11: 1195–205. [CrossRef]
de Oliveira BM, Medeiros MM, de Cerqueira JV, de Souza Quixadá RT, de Oliveira ÍM, et al. [Article in English, Portuguese] Metabolic syndrome in patients with rheumatoid arthritis followed at a University Hospital in Northeastern Brazil. Rev Bras Reumatol Engl Ed 2016; 56(2): 117–25. [CrossRef]
Chandrashekara S, Dhote SV, Anupama KR. The Differential Influence of Immunological Process of Autoimmune Disease on Lipid Metabolism: A Study on RA and SLE. Indian J Clin Biochem 2019; 34(1): 52–9.
Parra-Salcedo F, Contreras-Yáñez I, Elías-López D, Aguilar-Salinas CA, Pascual-Ramos V. Prevalence, incidence and characteristics of the metabolic syndrome (MetS) in a cohort of Mexican Mestizo early rheumatoid arthritis patients treated with conventional disease modifying anti-rheumatic drugs: the complex relationship between MetS and disease activity. Arthritis Res Ther 2015; 17: 34. [CrossRef]
Hannawi S, AlSalmi I, Moller I, Naredo E. Uric acid is independent cardiovascular risk factor, as manifested by increased carotid intima-media thickness in rheumatoid arthritis patients. Clin Rheumatol 2017; 36(8): 1897–902. [CrossRef]